Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.


Clinical Trial Description

The purpose of this study is to demonstrate the safety and characterize the immunogenicity of AZD1222; AstraZeneca's candidate ChAdOx1 vector vaccine against SARS-CoV-2 (nCoV-19) in previously unvaccinated immunocompromised adults. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05057897
Study type Interventional
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date December 22, 2021
Completion date July 28, 2023